Your browser doesn't support javascript.
loading
Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.
Gaborit, Benjamin; Vanhove, Bernard; Vibet, Marie-Anne; Le Thuaut, Aurélie; Lacombe, Karine; Dubee, Vincent; Ader, Florence; Ferre, Virginie; Vicaut, Eric; Orain, Jéremie; Le Bras, Morgane; Omnes, Anne; Berly, Laetitia; Jobert, Alexandra; Morineau-Le Houssine, Pascale; Botturi, Karine; Josien, Régis; Flet, Laurent; Degauque, Nicolas; Brouard, Sophie; Duvaux, Odile; Poinas, Alexandra; Raffi, François.
Afiliación
  • Gaborit B; CHU Nantes, Department of Infectious Disease, Clinical Investigation, Nantes, France.
  • Vanhove B; CHU Nantes and Inserm, Clinical Investigation Centre CIC1413, Nantes, France.
  • Vibet MA; Xenothera, Nantes, France.
  • Le Thuaut A; CHU Nantes, Sponsor Department, Nantes, France.
  • Lacombe K; CHU Nantes, Sponsor Department, Nantes, France.
  • Dubee V; Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, INSERM, AP-HP, Hôpital Saint-Antoine, Service des Maladies Infectieuses et Tropicales, Paris, France.
  • Ader F; CHU Angers, Service de Maladies Infectieuses et Tropicales, Angers, France.
  • Ferre V; Centre International de Recherche en Infectiologie (CIRI), Inserm 1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, F-69007, Lyon, France.
  • Vicaut E; Département des Maladies infectieuses et tropicales, Hospices Civils de Lyon, F-69004, Lyon, France.
  • Orain J; CHU Nantes and Inserm, Clinical Investigation Centre CIC1413, Nantes, France.
  • Le Bras M; CHU Nantes, Virology Laboratory, Nantes, France.
  • Omnes A; APHP, Department of Biostatistics, Université Paris-Diderot, Sorbonne-Paris Cité, Fernand Widal Hospital, Paris, France.
  • Berly L; CHU Nantes, Department of Infectious Disease, Clinical Investigation, Nantes, France.
  • Jobert A; CHU Nantes and Inserm, Clinical Investigation Centre CIC1413, Nantes, France.
  • Morineau-Le Houssine P; CHU Nantes, Department of Infectious Disease, Clinical Investigation, Nantes, France.
  • Botturi K; CHU Nantes and Inserm, Clinical Investigation Centre CIC1413, Nantes, France.
  • Josien R; CHU Nantes, Sponsor Department, Nantes, France.
  • Flet L; CHU Nantes, Sponsor Department, Nantes, France.
  • Degauque N; CHU Nantes, Sponsor Department, Nantes, France.
  • Brouard S; CHU Nantes, Department of Infectious Disease, Clinical Investigation, Nantes, France.
  • Duvaux O; CHU Nantes and Inserm, Clinical Investigation Centre CIC1413, Nantes, France.
  • Poinas A; CHU Nantes, Partnership and Innovation Department, Nantes, France.
  • Raffi F; Nantes Université, CHU Nantes, Inserm, Centre de Recherche en Transplantation et Immunologie, UMR 1064, ITUN, F-44000, Nantes, France.
Trials ; 22(1): 199, 2021 Mar 09.
Article en En | MEDLINE | ID: mdl-33750432
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Anticuerpos Neutralizantes / COVID-19 Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Francia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Anticuerpos Neutralizantes / COVID-19 Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2021 Tipo del documento: Article País de afiliación: Francia